Exploration of Targeted Anti-tumor Therapy’s Post

🔬 Exciting News in Liver Tumor Diagnosis! 🔍 Thrilled to announce that BioGenex has unveiled the game-changing anti-Arginase-1 antibody a breakthrough tool revolutionizing liver tumor diagnosis. 🚀 Arginase 1 (ARG1), or liver-type arginase, plays a pivotal role in breaking down L-arginine into ornithine and urea. This enzymatic activity, primarily found in hepatocytes, serves as a crucial marker for hepatocellular carcinoma (HCC). 📈 Our recent study confirmed Arginase-1 positivity in a remarkable 84.1% of HCC cases (37 out of 44), highlighting its unparalleled significance. As a result, Arginase-1 emerges as an invaluable and highly sought-after marker, enabling precise and effective differential diagnosis of hepatocellular carcinoma from metastatic tumors affecting the liver. 🛡️ Why BioGenex? We provide ready-to-use (RTU) and concentrated forms of antibodies, tailored for both manual and automated systems. Our products are best-in-class for clinicopathological diagnosis and drug discovery. Empowering pathologists and clinicians, BioGenex facilitates precise diagnosis, ultimately contributing to improved life expectancy. Learn More: https://hubs.la/Q02mG6vz0 #LiverTumorDiagnosis #BioGenexInnovation #CancerResearch #MedicalBreakthroughs

𝐑𝐚𝐝𝐢𝐨𝐋𝐢𝐠𝐚𝐧𝐝 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 (𝐑𝐋𝐓): 𝐀 𝐆𝐫𝐨𝐮𝐧𝐝𝐛𝐫𝐞𝐚𝐤𝐢𝐧𝐠 𝐀𝐩𝐩𝐫𝐨𝐚𝐜𝐡 𝐢𝐧 𝐂𝐚𝐧𝐜𝐞𝐫 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 🎯 RLT is emerging as a highly promising therapy that uses radiolabeled molecules to precisely target cancer cells. By combining a radioactive isotope with a ligand, this therapy delivers radiation directly to the tumor or metastatic site, causing cancer cell death while minimizing harm to surrounding healthy tissues. Unlike traditional therapies that have broader systemic effects, RLT offers a more targeted and effective treatment for certain cancers. 𝐊𝐞𝐲 𝐀𝐝𝐯𝐚𝐧𝐭𝐚𝐠𝐞𝐬 𝐎𝐯𝐞𝐫 𝐓𝐫𝐚𝐝𝐢𝐭𝐢𝐨𝐧𝐚𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬: 𝟏. 𝐏𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲: RLT uses delivery vehicles that bind specifically to cancer cells or accumulate by physiological mechanisms unique to tumors, reducing damage to healthy tissues. 𝟐. 𝐌𝐢𝐧𝐢𝐦𝐚𝐥 𝐓𝐨𝐱𝐢𝐜𝐢𝐭𝐲: Compared to chemotherapy, RPT shows remarkable efficacy with minimal side effects such as hair loss or peripheral neuropathy, and significant responses are observed after just one or a few injections. 𝐂𝐮𝐫𝐫𝐞𝐧𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐚𝐧𝐝 𝐓𝐫𝐢𝐚𝐥𝐬: According to ClinicalTrials.gov, RLT is undergoing extensive clinical trials, with numerous studies in early-phase and phase 1 trials. Exciting developments are expected in the next few years, as more advanced phases show promising results. #RadioLigandTherapy #RLT #CancerResearch #PrecisionMedicine #TargetedTherapy

β-glucan, known as a potent adjuvant in immunotherapy, shows promise as an additional treatment for digestive tract tumors, such as colorectal, pancreatic, and gastric cancers. It has demonstrated anti-tumor efficacy in preclinical studies and may help reduce adverse reactions from chemotherapy while enhancing patients' quality of life. Further research is necessary to evaluate its full therapeutic potential and biological mechanisms for gastrointestinal tumor treatment. #βglucan #immunotherapy #digestivetracttumors #cancerresearch #bioadjuvant Read more here: https://lnkd.in/e7Re8w2C BioMedHack.com is your leading source for the latest news, breakthroughs, and insights in medicine, biohacking, and alternative medicine. Our mission is to help you live healthier and longer by bringing you cutting-edge information and expert advice. Follow us on Facebook, Instagram, and X.

43% of treating physicians treat lung cancer patients before having biomarker results - findings from a new survey presented at recent #IASLC conference. https://lnkd.in/ddaAdNnD The survey on almost 1700 individuals showed an improvement in testing frequency and perception, with more patients being tested globally (Good news!). However, the progress is still limited by obstacles to testing such as cost (27.2%), time (13.9%), and sample quality (13.8%). Pathologists report insufficient tissue is the most impactful reason testing is not performed in late-stage (48%), 39% use reflex biomarker testing as standard practice. Respondents suggested strategies to enhance biomarker testing, including education, streamlined clinical processes, increased funding, and policy changes. It's great to see these improvements but this survey also shows that there's still a long way to go. #precisiononcology #biomarkers #biomarkertesting

This study demonstrated that combining a #ketogenic diet with #metformin significantly reduces tumor growth and improves survival in mouse models of triple-negative breast cancer. By lowering blood glucose levels through carbohydrate restriction and inhibition of gluconeogenesis, hypoxic tumors—highly dependent on glucose—exhibited: • 66% reduction in tumor burden • 38% slower tumor growth • 36% increase in tumor latency • 31-day extension in median survival (equivalent to approximately 3 human years) The combination of a ketogenic diet and metformin leverages the glycolytic dependency of hypoxic tumors, offering a promising therapeutic strategy to complement existing treatments and improve clinical outcomes in glycolytic tumor types. Full text: https://lnkd.in/dyGXjsgT #ketodiet #ketogenicdiet #keto #chetogenica #dietachetogenica

📢 Abstract ”Angiogenesis, the formation of new blood vessels, plays a crucial role in the progression and metastasis of various cancers, including head and neck squamous cell carcinoma (HNSCC). HNSCCs are characterized by altered levels of angiogenesis-related factors, including the overexpression of pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), as well as the dysregulation of angiogenesis inhibitors. Together, these factors drive the formation of new blood vessels within the tumor microenvironment and are considered therapeutic targets in HNSCC. Although preclinical studies are promising, challenges have emerged in the clinical use of anti-angiogenic agents in the clinic, including treatment-related toxicities and the development of resistance to therapy. There is an unmet need for further research to elucidate the molecular pathways involved in HNSCC angiogenesis, identify novel therapeutic targets, and discover predictive biomarkers to improve patient selection.“ 📕 Read more: https://lnkd.in/gumUVDy4 Authors: Felix Nieberle, Steffen Spoerl, Alicja Głuszko, Juergen Taxis, Gerrit Spanier, Ramona Erber, Silvia Spoerl, Mirosław J. Szczepański, Philipp Beckhove, Torsten E. Reichert, Theresa L. Whiteside, Nils Ludwig

Cancer patients often suffer from pain, significantly affecting their quality of life, with a prevalence estimated at 44.5%. To address this, researchers have turned to β-cyclodextrins (β-CD) complexes, aiming to overcome limitations posed by compounds like p-Cymene (PC), known for its antinociceptive effects but hampered by its lipophilicity. This study focused on obtaining, characterizing, and assessing the impact of the p-cymene and β-cyclodextrin (PC/β-CD) complex in a cancer pain model. For a deeper insight, click on the link and read Eva Fenyvesi's blog post on Cyclodextrin News: https://lnkd.in/diwCYsEP #cyclolab #cyclodextrin #betacyclodextrin #cancer #cancerpain #cancertherapy #pain #painmanagement #naturalproducts #monoterpenes #inclusioncomplex #science #chemistry #research

🔬 BioGenex Presents Villin: A Game-Changing Biomarker for Colorectal Micropapillary Carcinomas Did you know? Villin is a 95-kDa F-actin protein belonging to the gelsolin family and is pivotal in identifying reverse polarity in colorectal micropapillary carcinomas. Unlike gelsolin, Villin is exclusively expressed in brush border epithelial cells, making it a highly specific marker for gastrointestinal adenocarcinomas, colorectal cancer, and beyond. 📊 Villin also aids in diagnosing cervical, endometrial, renal, pancreatic, lung, prostate, and ovarian carcinomas. BioGenex offers: ✔️ Ready-to-Use (RTU) & Concentrated Antibodies ✔️ Solutions for Manual & Automated Systems ✔️ Precision for Clinicopathological Diagnosis & Drug Discovery Transform your diagnostic accuracy today! Learn more: https://hubs.la/Q02-G_Xt0 #ColorectalCancer #CancerDiagnosis #Biomarker #BioGenex #PrecisionMedicine

Join us on September 17, 2024, from 10-11 AM EST for an insightful webinar with Dr. Andrew Satterlee, as he discusses the cutting-edge advancements in functional drug screening of patient tumor tissues. Learn how his innovative ex vivo platform is transforming cancer treatment by accelerating pre-clinical drug testing and providing actionable insights for personalized medicine. Save the date and register for free: https://lnkd.in/eV6R5G57 Don’t miss this opportunity to explore how these technologies are shaping the future of oncology research! #CancerResearch #PrecisionMedicine #PrecisionaryInstruments #compresstome #microtomes #vibratingmicrotomes #vibratomes #tissuesectioning #precisioncuttissuesslices #tissueslicing #laboratoryequipment #labsolutions